TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30054173
Drug: Therapist-led VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapist-led VR exposure therapy followed by a four-week internet-administered VR to in-vivo transition program
Study: 23095369
Drug: hMG-HP (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG-HP (150 IU hMG-HP daily for a maximum of 16 days)
Study: 17374817
Drug: Drug intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug intervention trials
Study: 17374817
Drug: Concomitant medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant medication use and comorbidities
Study: 78529
Drug: Flutamide 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 1.5 gm daily
Study: 78529
Drug: Flutamide 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 0.75 gm daily
Study: 78529
Drug: Flutamide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 1.0 mg diethylstilbestrol daily
Study: 21596243
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral cataract surgery
Study: 29241450
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine
Study: 8914461
Drug: Low-dose etoposide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etoposide
Study: 23590265
Drug: Ivacaftor (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor (150 mg orally every 12 hours for 48 weeks)
Study: 19095219
Drug: Duloxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine treatment
Study: 9465239
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) measurement of visceral/subcutaneous adipose thickness
Study: 9465239
Drug: Computed Tomography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computed Tomography (CT) measurement of visceral/subcutaneous adipose thickness
Study: 7870930
Drug: remoxipride 100
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: remoxipride 100 mg
Study: 7870930
Drug: remoxipride 100
Normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: remoxipride 100 mg plus biperiden 4 mg
Study: 7870930
Drug: biperiden 4
Normalized name: biperiden 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: biperiden 4 mg
Study: 2876573
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol
Study: 2876573
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg celiprolol plus 12.5 mg chlorthalidone
Study: 30794658
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg)
Study: 27046312
Drug: Topiramate (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (50-200 mg per day for 12 weeks)
Study: 24998293
Drug: Passive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive physical therapy (Control Group)
Study: 21741107
Drug: HbA1c≥5.7% and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbA1c≥5.7% and/or FPG≥5.6mmol/l
Study: 12629661
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment for hepatitis C virus
Study: 6362125
Drug: Albendazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (single 400 mg oral dose)
Study: 6362125
Drug: Albendazole (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (three consecutive days at the same daily dose level)
Study: 10779814
Drug: 20 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg/kg oral granisetron solution
Study: 10779814
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of granisetron (20 microg/kg and 40 microg/kg)
Study: 8773915
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (primed continuous infusion from t = 1 h to t = 5 h)
Study: 8773915
Drug: No amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No amino acid infusion (control group)
Study: 20167702
Drug: Avosentan 25
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avosentan 25 mg/d
Study: 20167702
Drug: Avosentan 50
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avosentan 50 mg/d
Study: 15956269
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg/day combined with sertraline 100 mg/day and psychosocial support
Study: 15956269
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with sertraline 100 mg/day and psychosocial support
Study: 11931398
Drug: Once-weekly 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly 600 mg rifapentine + 15 mg/kg isoniazid (HRp1)
Study: 11931398
Drug: Thrice-weekly isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thrice-weekly isoniazid + rifampicin (HR3)
Study: 9815520
Drug: Clodronate 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 1,600 mg orally per day for 2 years
Study: 7655833
Drug: ICE regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICE regimen (cisplatin: 20 mg/m2 x day x 5, ifosfamide: 1.8 g/m2 x day x 5, mesna: 1.2 g/m2 x day x 5, etoposide: 100 mg/m2 x day x 5)
Study: 7655833
Drug: CE regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE regimen (cisplatin: 20 mg/m2 x day x 5, etoposide: 100 mg/m2 x day x 5)
Study: 2462343
Drug: Encainide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide administered twice daily (group A)
Study: 2462343
Drug: Encainide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encainide administered three times daily (group B)
Study: 29481979
Drug: 0, 6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0, 6, 12, or 18 sessions of spinal manipulative therapy (SMT)
Study: 26843373
Drug: TAU (treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (treated as usual with antipsychotics)
Study: 16000606
Drug: Adjuvant cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant cisplatin-based chemotherapy (300-400 mg/m2) for 3-4 cycles
Study: 20978195
Drug: Adjuvant cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant cisplatin-based chemotherapy
Study: 12873248
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day dexamphetamine (n = 16)
Study: 2065826
Drug: Antituberculous drugs
Normalized name: ANTITUBERCULARS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antituberculous drugs only
Study: 2065826
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide and furosemide in addition to antituberculous treatment
Study: 6406460
Drug: Bupropion (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (12.5 mg to 100 mg)
Study: 22794217
Drug: 2 mg/mL
Normalized name: urea 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/mL berberine
Study: 318908
Drug: Butorphanol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 2.0 mg
Study: 2020612
Drug: Butorphanol 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 3.0 mg
Study: 2020612
Drug: Butorphanol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (all doses)
Study: 20520283
Drug: Haloperidol 4
Normalized name: haloperidol 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 4 mg BID
Study: 21755540
Drug: Asenapine 10
Normalized name: asenapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 10 mg BID
Study: 10622345
Drug: Fluoxetine (FLU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (FLU), 20 mg QD for 11 weeks
Study: 2019135
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and conventional amino acid solution
Study: 2019135
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and branch-chain amino acid enriched solution
Study: 2019135
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusions
Study: 7046898
Drug: Chlorpromazine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (300 mg to 2100 mg)
Study: 7046898
Drug: Pimozide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide (10 to 70 mg)
Study: 21211560
Drug: Polyherbal formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyherbal formulation (Geriforte tablets)
Study: 9056163
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg p.o./d/2 weeks/3 months)
Study: 9056163
Drug: Calcidiol (32,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcidiol (32,000 IU/weekly)
Study: 8368227
Drug: Pamidronate 30
Normalized name: pamidronate 30 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 30 mg
Study: 8368227
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg
Study: 23078156
Drug: HBD3 peptide
Normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBD3 peptide gel
Study: 17258626
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel (CHX)
Study: 23078156
Drug: Mismatched peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mismatched peptide gel (MP)
Study: 18458163
Drug: Salt tablets
Normalized name: bile salts Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt tablets (200 mmol/d of sodium)
Study: 29576001
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg per day)
Study: 26367217
Drug: melphalan 200
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: melphalan 200 mg/m² (mel200)
Study: 24375768
Drug: Alisporivir (ALV)
Normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir (ALV) 1000 mg once-daily
Study: 24375768
Drug: Alisporivir (ALV)
Normalized name: ALV-001
DrugBank: Alisporivir (DB12139)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisporivir (ALV) 400 mg with RBV 400 mg twice-daily for 36 weeks
Study: 24375768
Drug: Response-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-guided treatment
Study: 12401850
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline 200 mg b.d. 24 h before and for 48 h after CAG
Study: 2792172
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of frusemide without plasma volume expansion
Study: 2792172
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of dextran
Study: 88754
Drug: Chemotherapy (methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (methotrexate 400 mg followed by citrovorum factor 100 mg + bleomycin 60 mg/week for the first 15 weeks)
Study: 88754
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Chemotherapy, Immunotherapy, No treatment)
Study: 21471550
Drug: Tramadol/paracetamol (37.5+325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol/paracetamol (37.5+325 mg)
Study: 21471550
Drug: Paracetamol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol monotherapy (1000 mg)
Study: 19258386
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LP: 0.6-0.8 g/kg IBW/day)
Study: 16750450
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER 10 mg q12h
Study: 29297732
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg or 300 mg)
Study: 29297732
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg with possible increase to 300 mg)
Study: 27300645
Drug: ONO-9054 10
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-9054 10 μg/mL
Study: 7729019
Drug: Medical group
Normalized name: ALCOHOL 266.1615 mL in 354.882 mL TOPICAL GEL [Iconic Medical Group Hand Sanitizer - 12oz 12oz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical group (nonsurgical therapy)
Study: 7426351
Drug: Influenza virus
Normalized name: Influenza virus Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza virus RIT 4050 (H3N2) vaccine
Study: 21563871
Drug: Milk supplemented
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk supplemented with 5 ppm fluoride and probiotic bacteria (Lactobacillus rhamnosus LB21, 10^7 CFU/mL)
Study: 31862830
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment alone (ST group)
Study: 20516439
Drug: MP-T (melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP-T (melphalan plus prednisone plus thalidomide 200 mg/d)
Study: 10606935
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (n = 6)
Study: 6432417
Drug: Auranofin 6
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auranofin 6 mg/day
Study: 6432417
Drug: D-penicillamine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine 500 mg/day
Study: 28099485
Drug: AS03-adjuvanted H5N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H5N1 vaccine
Study: 17302879
Drug: DHEA 50-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50-mg
Study: 14759617
Drug: NuvaRing with
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuvaRing with a single dose of antimycotic
Study: 3130256
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (VPA) 500 mg t.i.d. for 5 days
Study: 3130256
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (VPA) in epileptic patients on established monotherapy
Study: 26556955
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and ropivacaine
Study: 8211671
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation with a dose per fraction of 2 Gy
Study: 8211671
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation with a dose per fraction of 3 Gy
Study: 8211671
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation with a dose per fraction of 4 Gy
Study: 8211671
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation with a dose per fraction of 5.4 Gy
Study: 2869723
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg dezocine
Study: 29856817
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH), 5000 IU twice daily
Study: 25296661
Drug: Flurbiprofen 8.75
Normalized name: flurbiprofen 8.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 8.75 mg lozenge
Study: 15688086
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg ghrelin (i.v. bolus injection)
Study: 12441831
Drug: Alfentanil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil and ketamine infusions targeting plasma concentrations of 75 ng/ml for alfentanil and 150 ng/ml for ketamine
Study: 31673898
Drug: Carfilzomib in
Normalized name: carfilzomib Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib in combination with lenalidomide and dexamethasone (KRd)
Study: 30109404
Drug: 4-ml hyaluronic
Normalized name: rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4-ml hyaluronic acid treatment
Study: 30109404
Drug: SVF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVF treatment
Study: 24800919
Drug: 6-mercaptopurine capsules
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine capsules
Study: 18751689
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily (40QD)
Study: 18751689
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg twice daily (20TD)
Study: 17900462
Drug: Carotid‐derived augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotid‐derived augmentation index
Study: 15006018
Drug: budesonide/formoterol adjustable
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol adjustable maintenance dosing (AMD)
Study: 8030598
Drug: Complete L-amino
Normalized name: L-α-amino-γ-methylmercaptobutyric acid
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complete L-amino acid mixture diet (group 3)
Study: 31407937
Drug: Interpersonal Therapy‐Adolescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal Therapy‐Adolescent Skills Training
Study: 28225835
Drug: Half dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half dose of mulberry-extract (Reducose)
Study: 28225835
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose of mulberry-extract (Reducose)
Study: 28225835
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of mulberry-extract (Reducose)
Study: 8103611
Drug: Oral sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sotalol treatment (pre- and postoperative)
Study: 8103611
Drug: Routine beta-blocking
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine beta-blocking treatment (half the preoperative dose)
Study: 3029592
Drug: Initial radiotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial radiotherapy plus chemotherapy
Study: 3029592
Drug: Delayed radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed radiotherapy plus chemotherapy
Study: 30737932
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment with poor quality root filling and poor quality crown restoration (PE + PR)
Study: 30737932
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment with root posts
Study: 30737932
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment without root posts
Study: 24168514
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral isotretinoin (ISO), 20 mg/day for six months
Study: 12572927
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg of intravenous L-carnitine at the end of each hemodialysis treatment (Group A)
Study: 10601747
Drug: Discourse-dependent semantic
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discourse-dependent semantic anomalies (e.g., 'slow')
Study: 30969260
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa (daily subcutaneous injections)
Study: 29716784
Drug: Emixustat 5
Normalized name: Emixustat
DrugBank: Emixustat (DB12608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emixustat 5 mg
Study: 29716784
Drug: Emixustat 10
Normalized name: Emixustat
DrugBank: Emixustat (DB12608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emixustat 10 mg
Study: 9394172
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus exposure to pulsed magnetic fields (PMF) for four weeks (sinusoidal form, 0.95 to 1.05 Hz, amplitude +/- 2400 nano Teslas)
Study: 22978771
Drug: Quetiapine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (750 mg/day)
Study: 20162509
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for 3 weeks (n = 20)
Study: 16142551
Drug: Extended-release oxybutynin
Normalized name: oxybutynin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin chloride 10 mg/day
Study: 16142551
Drug: Extended-release tolterodine
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release tolterodine tartrate 4 mg/day
Study: 8949620
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg and caffeine 50 mg
Study: 8949620
Drug: Paracetamol 400
Normalized name: Hydrocodone bitartrate 5 mg and paracetamol 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 400 mg and dextropropoxyphene 30 mg
Study: 7178370
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg i.v.)
Study: 27001374
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of two implants supporting mandibular overdentures (T3)